Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 13INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Neoplasms 3210Carcinoma, Non-Small-Cell Lung 2721Breast Neoplasms 2547Colorectal Neoplasms 1454Prostatic Neoplasms 1303Neoplasm Metastasis 1292Multiple Myeloma 1109Melanoma 1101Ovarian Neoplasms 1001Lung Neoplasms 941Recurrence 921Leukemia, Myeloid, Acute 876Pancreatic Neoplasms 830Lymphoma, Non-Hodgkin 766Lymphoma 713Stomach Neoplasms 691Carcinoma, Renal Cell 658Carcinoma, Hepatocellular 645Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 546Lymphoma, Follicular 515Head and Neck Neoplasms 488Glioblastoma 472Small Cell Lung Carcinoma 444Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 433Advanced Solid Tumors 430Leukemia 426Uterine Cervical Neoplasms 418Urinary Bladder Neoplasms 405

Interventions

sintilimab 1pembrolizumab 1durvalumab 1Injections 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Biliary Tract Cancer × Clear all
NCT07229625 2026-01-28

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
604 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

NCT06978114 2025-07-02

A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Recruiting
46 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

NCT05653180 2023-04-03

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Unknown
20 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

NCT02597465 2020-12-14

A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507

Sun Pharma Advanced Research Company Limited

Phase 3 Withdrawn
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡